Objective
USA’s top Pharmaceutical company wanted to understand the licensing opportunity within the various solid tumor indications between 2016 and 2022. The key objective of the research was to build,
- Comprehensive Database: Compile and analyze data from diverse sources to create a robust database of licensing collaborations in various solid tumor indications between 2016 and 2022
- Strategic Decision Support and Benchmarking: Provide strategic decision support by initiating the collection and benchmarking of global transaction data, focusing on volumes and financial terms within selected indications and markets.
Approach
Developed a suitable business model based on the corporate strategy, encompassing options such as organic growth, distributorship, licensing, joint ventures, partnerships, M&A, and franchising. The approach involves the following steps:
- Compiled data from various sources, including secondary research, company websites, and private equity reports, resulting in a database comprising 350+ licensing collaborations spanning various solid tumor indications within the 2016-2022 timeframe
- Initiate the collection of benchmarking data on global transactions, including volumes and financial terms, within the selected indications and markets
- Defining deal parameters to be analyzed for selecting relevant deals and conducting benchmarking
- Further narrow down the datasets using assumptions and filters, such as global, regional, and local deals, based on transaction size, market coverage, upfront payments, etc.
- Focusing on transactions where higher economic value is likely at stake
- For regional business licensing deals, we narrowed our focus to territory deals that are either Japan, China, Latin America, or EU-centric, capturing the information at the regional level by relying on press releases or other local data source indicating the involvement of a license or JV in the transaction
Outcome
The research output has equipped the client with a comprehensive and strategic understanding of the licensing landscape within the solid tumor indications market. The compiled database, enriched with data from diverse sources, has offered insights into successful licensing collaborations spanning 2016-2022. The benchmarking data has provided a clear view of global transaction trends, enabling the client to assess the financial terms and volumes associated with similar deals. This enhanced understanding empowered the client to make strategic, data-driven choices in building and optimizing their portfolio.
